2011 Scrip 100: All aboard Teva's bullet train
This article was originally published in Scrip
The global pharma industry is closely watching a company that has a stated aim of doubling its sales by 2015, aided by an ambitious branded product strategy and cash to spend on strategic acquisitions. This is how Teva will build its business in the post-Copaxone-protected era, CEO Shlomo Yanai tells Ashley Yeo.
You may also be interested in...
The latest guidance from the UK devices regulator fills in some of the information gaps for companies addressing the Northern Ireland and EU27 markets after this year, seen through the lens of Brexit.
Johnson & Johnson's Ashley McEvoy explains how the global medtech business should change, seen through the lens of the coronavirus pandemic.
COVID-19 business volatility continues to impact the medtech industry, but Royal Philips is targeting modest comparable sales growth for 2020 after posting quarterly growth of 10%.